Ukraine advances access to innovative therapies through HTA and managed entry agreements

Ukraine continues to strengthen its health care system through significant reforms in pricing, reimbursement, and access to innovative therapies.

Since 2021, the Ukrainian government has adopted regulations on health technology assessment (HTA), managed entry agreements (MEA), and national guidelines for HTAs of medicines, gradually aligning the country’s approach with best international practices. These efforts were introduced to boost pharmacoeconomics-based decision-making on coverage and reimbursement, promote access to effective health technologies, and ensure greater transparency in public health care funding.

Since 2021, the CMS Life Sciences and Healthcare team in Ukraine has been at the forefront of HTA and MEA, advising global innovative life sciences clients on market access strategies, HTA, centralised, regional, local and hospital procurement, pricing, reimbursement and MEA. CMS has also represented leading global pharmaceutical companies in dialogue with the key stakeholders concerning HTA, pricing and reimbursement.  

CMS analysis

Our lawyers have prepared a detailed overview of developments in HTA and MEA in Ukraine. The analysis includes:

•    A timeline of legislative and practical milestones of HTA and MEA;

•    Key statistics on HTA procedures, dossier types, therapeutic areas, and signed MEAs;

•    Practical takeaways from implementation experience;

•    Insights into the ongoing policy dialogue and expected legislative and regulatory developments.

To access this material, follow this link HTA and MEA in Ukraine. 

For more information, contact your CMS client partner or these experts on the CMS Ukraine team: Borys Danevych, Mykhailo Sus.